Samil Pharmaceutical Co.,Ltd announced a private placement of 19th series nregistered coupon unguaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on July 26, 2022. The transaction will include participation from DB KOSDAQ Venture General Private Equity Investment Trust No. 3 for KRW 600,000,000, DBGreen Multi-Strategy General Private Equity Trust No.

1 for KRW 400,000,000, NH Absolute Return General Private Equity Trust No. 1 of for KRW 600,000,000, NH Absolute KOSDAQ Venture Mezzanine Specialized Investment Private Equity Trust No. 1 for KRW 600,000,000, NH Absolute KOSDAQ Venture Mezzanine Alpha General Private Equity Trust No.

1 for KRW 200,000,000, NH Absolute Mezzanine General Private Equity Trust No. 3 for KRW 600,000,000, Orion The banks 2 General Private Equity Trust for KRW 1,000,000,000 and Ace Leading New Technology Fund 2 for KRW 1,000,000,000. The bonds does not carry any interest rate.

The bonds will mature on July 28, 2027. The bonds will be fully convertible into 606,648 shares of the company at a fixed conversion price of KRW 8,242 between the period of July 2, 2023 to June 28, 2027. The payment date is July 28, 2022.

The transaction has been approved by the board of directors of the company.